June 3, 2025 7:52am

Keep breadth improving; only incessant news flow will stimulate any share pricing upside

Despite volatility continuing to persist at elevated levels

News: Agenus (AGEN +$0.79 pre-open) and Zydus Lifesciences (NSE: ZYDUSLIFE) enter $141M Strategic Collaboration to advance BOT/BAL, expand Zydus’ Biologics Manufacturing in the US. Beam Therapeutics (BEAM +$0.17 pre-open) the U.S. FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Pre-open Indications: 1 Sell into Strength, 1 Negative and 4 Positive

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

 

Monday’s night’s … RegMed Investors (RMi) Closing Bell: sector thrives on acquisition, partner and regulatory news … https://www.regmedinvestors.com/articles/13942

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The pre-open Dow futures are DOWN -0.23% or (-98 points), the S&P futures are DOWN -0.16% or (-9 points) and the Nasdaq futures are DOWN -0.05% or (-11 points)

  • Stock futures were slipping on Tuesday, 6/3
  • European stock markets were mostly in the red,
  • Asia-Pacific markets trade mixed as investors assess dismal China factory activity

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Monday: The Dow closed UP +35.41points or +0.08%, the S&P closed UP +24.25 points or +0.41% while the Nasdaq closed UP +128.85 points or +0.67%

  • Friday: The Dow closed UP +54.34 points or +0.13%, the S&P closed DOWN -0.48 points or -0.01% while the Nasdaq closed DOWN -62.11 points or -0.32%
  • On Friday, closing out the month of May the S&P 500 gained 6%, its best monthly performance since November 2023. The Nasdaq surged more than 9% for the month and the Dow rose about 4%.

Economic Data Docket:  JOLTS and Manufacturing, Shipments, and Orders

 

Q2 – June – 1 positive session

  • May – 1 market holiday, 10 negative and 11 positive closes
  • Q2 - April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although:

  • Beam Therapeutics (BEAM) closed up +$0.36 after Friday’s -$0.49 with a positive +$0.17 or +1.05% pre-open
  • CRISPR Therapeutics (CRSP) closed up +0.66 after Friday’s -$0.49 with a positive +$0.37 or +1% pre-open
  • Moderna (MRNA) closed up +$0.49 after Friday’s -$0.37 with a negative -$0.09 or -0.33% pre-open
  • Agenus (AGEN) closed up +$0.70 after Friday’s +$0.23 with a positive +0.79 or +19.13% pre-open on news
  • Caribou Biosciences (CRBU) closed down -$0.0851 after Friday’s -$0.10 with a positive +$0.03 or +7.70%
  • Sell into Strength: Verve Therapeutics (VERV) closed up +0.345 after Friday’s -$0.15 with a positive +0.03 or +10.73%

 

The BOTTOM LINE: Not a clairvoyant, there are session that are just a flip-of-the-coin

U.S. stock index futures fell on Tuesday as investors awaited possible negotiations between the U.S. and its trading partners for more clarity on the tariff war that has roiled financial markets for months.

  • The Trump administration wants countries to provide their best offer on trade negotiations by Wednesday as officials seek to accelerate talks with multiple partners ahead of a self-imposed deadline in just five weeks, according to a draft letter to negotiating partners <Reuters>.

June ’25:

  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

May ’25 last week: understand the “flow” of bad market and economic karma…

  • 5/30 – Friday closed negative with 6 positive, 26 negative and 3 flats
  • 5/29 –Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/28 -Wednesday closed negative with 7 positive, 26 negative and 2 flats
  • 5/27 - Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 5/26 - Monday. Market closed - holiday

 

Later this week, investors will receive the latest U.S. jobs-market update from the Labor Department. For weeks now, investors have been waiting and watching for an “ah-ha” moment in the economic data that would signal, in no uncertain terms, that the U.S. economy is heading for a recession, said Callie Cox, chief market strategist at Ritholtz Wealth Management. <MarketWatch>

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • As I also wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.